Clinical trials highlight their effectiveness compared to conventional chemotherapy by reactivating T cells within the tumor mass, specifically for a subgroup of patients with tumors overexpressing PD-L1 as a response to a robust and active immune infiltrate (Bruni et al., 2020). Here, CD274 is linked to neoplasm.